Watanabe, Sanae <br/><br/>
Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.  [electronic resource] 

 -  Clinical and experimental hypertension (New York, N.Y. : 1993)  Jul 2006 
 - 451-61 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1064-1963 
<br/><br/><label>Standard No.: </label>10.1080/10641960600798671  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Albuminuria--drug therapy<br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>Antihypertensive Agents--therapeutic use<br/>Biomarkers--blood<br/>Blood Flow Velocity--drug effects<br/>Blood Pressure--drug effects<br/>Creatinine--blood<br/>Cystatin C<br/>Cystatins--blood<br/>Female<br/>Humans<br/>Hypertension--drug therapy<br/>Japan<br/>Kidney--blood supply<br/>Kidney Function Tests<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Pulsatile Flow--drug effects<br/>Renal Circulation--drug effects<br/>Tetrazoles--antagonists & inhibitors<br/>Treatment Outcome<br/>Ultrasonography, Doppler<br/>Valine--analogs & derivatives<br/>Valsartan<br/>Vascular Resistance--drug effects